ES2265918T3 - Uso de inhibidores de dipeptidil peptidasa iv para mejorar la fertilidad. - Google Patents

Uso de inhibidores de dipeptidil peptidasa iv para mejorar la fertilidad. Download PDF

Info

Publication number
ES2265918T3
ES2265918T3 ES00911186T ES00911186T ES2265918T3 ES 2265918 T3 ES2265918 T3 ES 2265918T3 ES 00911186 T ES00911186 T ES 00911186T ES 00911186 T ES00911186 T ES 00911186T ES 2265918 T3 ES2265918 T3 ES 2265918T3
Authority
ES
Spain
Prior art keywords
inhibitors
use according
treatment
therapeutic composition
obese
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00911186T
Other languages
English (en)
Spanish (es)
Inventor
Pierre Broqua
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring BV filed Critical Ferring BV
Application granted granted Critical
Publication of ES2265918T3 publication Critical patent/ES2265918T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES00911186T 1999-03-23 2000-03-21 Uso de inhibidores de dipeptidil peptidasa iv para mejorar la fertilidad. Expired - Lifetime ES2265918T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9906714.2A GB9906714D0 (en) 1999-03-23 1999-03-23 Compositions for improving fertility
GB9906714 1999-03-23

Publications (1)

Publication Number Publication Date
ES2265918T3 true ES2265918T3 (es) 2007-03-01

Family

ID=10850229

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00911186T Expired - Lifetime ES2265918T3 (es) 1999-03-23 2000-03-21 Uso de inhibidores de dipeptidil peptidasa iv para mejorar la fertilidad.

Country Status (29)

Country Link
US (1) US7115650B1 (zh)
EP (1) EP1162969B1 (zh)
JP (1) JP2002539243A (zh)
KR (1) KR100689951B1 (zh)
CN (1) CN1196483C (zh)
AR (1) AR023129A1 (zh)
AT (1) ATE328594T1 (zh)
AU (1) AU765912B2 (zh)
CA (1) CA2366911C (zh)
CZ (1) CZ20013410A3 (zh)
DE (1) DE60028552T2 (zh)
DK (1) DK1162969T3 (zh)
ES (1) ES2265918T3 (zh)
GB (1) GB9906714D0 (zh)
HK (1) HK1046647B (zh)
HU (1) HUP0200410A3 (zh)
IL (1) IL145569A0 (zh)
MX (1) MXPA01009612A (zh)
MY (1) MY135683A (zh)
NO (1) NO20014607L (zh)
NZ (1) NZ514449A (zh)
PL (1) PL195779B1 (zh)
PT (1) PT1162969E (zh)
RU (1) RU2246944C2 (zh)
TR (1) TR200102647T2 (zh)
TW (1) TWI244920B (zh)
UA (1) UA77644C2 (zh)
WO (1) WO2000056296A2 (zh)
ZA (1) ZA200108083B (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
GB9928330D0 (en) * 1999-11-30 2000-01-26 Ferring Bv Novel antidiabetic agents
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002072582A1 (en) 2001-03-12 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Methods for the synthesis of densely functionalized pyrrolidine template libraries
GB0109146D0 (en) * 2001-04-11 2001-05-30 Ferring Bv Treatment of type 2 diabetes
US7183290B2 (en) 2001-06-27 2007-02-27 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
JP4300108B2 (ja) 2001-06-27 2009-07-22 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのピロリジン類
KR20040015298A (ko) 2001-06-27 2004-02-18 스미스클라인 비참 코포레이션 디펩티딜 펩티다제 억제제로서의 플루오로피롤리딘
DE60304911D1 (de) 2002-02-25 2006-06-08 Eisai Co Ltd Xanthin-Derivate als DPP-IV-Inhibitoren
US6710040B1 (en) 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
CN100348599C (zh) 2002-06-06 2007-11-14 卫材R&D管理有限公司 新的稠合咪唑衍生物
WO2005026114A1 (en) * 2003-09-17 2005-03-24 Pfizer Inc. Hiv protease inhibitors, compositions containing the same and their pharmaceutical uses
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
ZA200802857B (en) 2005-09-14 2009-09-30 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors for treating diabetes
KR101368988B1 (ko) 2005-09-16 2014-02-28 다케다 야쿠힌 고교 가부시키가이샤 디펩티딜 펩티다제 억제제
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US8247438B2 (en) 2008-02-27 2012-08-21 Neuropill, Inc. Methods for treating schizophrenia
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
MX2012011631A (es) 2010-04-06 2013-01-18 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
CA2812061A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012135570A1 (en) 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en) 2011-04-22 2014-02-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
US11096924B2 (en) * 2016-09-07 2021-08-24 Trustees Of Tufts College Combination therapies using immuno-dash inhibitors and PGE2 antagonists
EP3606527A1 (en) 2017-04-03 2020-02-12 Coherus Biosciences, Inc. Ppar-gamma agonist for treatment of progressive supranuclear palsy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05508624A (ja) 1990-04-14 1993-12-02 ニュー イングランド メデカル センター ホスピタルズ インク ジペプチジル―アミノベプチダーゼ・4型の阻害剤
WO1993008259A2 (en) * 1991-10-22 1993-04-29 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type iv
IL111785A0 (en) * 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US5952301A (en) 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function

Also Published As

Publication number Publication date
GB9906714D0 (en) 1999-05-19
EP1162969A2 (en) 2001-12-19
NO20014607D0 (no) 2001-09-21
MXPA01009612A (es) 2002-07-02
AR023129A1 (es) 2002-09-04
TWI244920B (en) 2005-12-11
MY135683A (en) 2008-06-30
DE60028552T2 (de) 2007-06-28
CN1196483C (zh) 2005-04-13
UA77644C2 (en) 2007-01-15
CA2366911C (en) 2010-01-19
WO2000056296A2 (en) 2000-09-28
DK1162969T3 (da) 2006-09-18
EP1162969B1 (en) 2006-06-07
KR20010108388A (ko) 2001-12-07
JP2002539243A (ja) 2002-11-19
AU3317700A (en) 2000-10-09
HK1046647A1 (en) 2003-01-24
US7115650B1 (en) 2006-10-03
CA2366911A1 (en) 2000-09-28
ZA200108083B (en) 2002-11-27
CN1352557A (zh) 2002-06-05
ATE328594T1 (de) 2006-06-15
HUP0200410A3 (en) 2002-09-30
NO20014607L (no) 2001-11-20
WO2000056296A3 (en) 2001-01-25
NZ514449A (en) 2002-11-26
IL145569A0 (en) 2002-06-30
AU765912B2 (en) 2003-10-02
KR100689951B1 (ko) 2007-03-08
HUP0200410A2 (en) 2002-08-28
PL350797A1 (en) 2003-02-10
HK1046647B (zh) 2005-09-30
PL195779B1 (pl) 2007-10-31
RU2246944C2 (ru) 2005-02-27
TR200102647T2 (tr) 2002-01-21
PT1162969E (pt) 2006-10-31
DE60028552D1 (de) 2006-07-20
CZ20013410A3 (cs) 2002-04-17

Similar Documents

Publication Publication Date Title
ES2265918T3 (es) Uso de inhibidores de dipeptidil peptidasa iv para mejorar la fertilidad.
US6521644B1 (en) Compositions for promoting growth
JP4169365B2 (ja) 不能症を処置するための、cGMP−ホスフォジエステラーゼインヒビターの用途
JP5846822B2 (ja) 栄養又は治療組成物
ITMI941048A1 (it) Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate
JP6010196B2 (ja) オキサゾリジノン含有二量体化合物、組成物、ならびに作製および使用方法
JP2003119155A (ja) 女性の性機能障害の治療及び女性の性機能障害の治療に有用な化合物の同定方法
JP2010248253A (ja) グルコース代謝を調節する方法、およびそれに関連する試薬
RU99100703A (ru) Модифицированная форма гидрохлорида r(-)-n -(4,4-ди(3-метил-тиен-2-ил)бут-3- енил)-нипекотиновой кислоты
WO2023003416A1 (ko) 전신경화증의 예방 또는 치료용 약학적 조성물